Hello Health Rounds Readers! Today we highlight research findings reported at ESMO 2024, the annual meeting of the European ...

Notably, patients benefited from pembrolizumab regardless of whether they achieved a pathologic complete response (pCR), ...

A shorter radiotherapy (RT) course proved its mettle in early-stage breast cancer in terms of lymphedema risk, without ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease1 New results show potential of amivantamab beyond lung cancer1 BEERSE, BELGIUM, ...

BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with ...

Key oncology conferences like ASCO, ASH, and ESMO drive investment-informing clinical research, with recent ESMO 2024 data highlighting significant advancements in immunotherapy. Merck's ...

Jazz’s Global Head of R&D Robert Iannone, M.D., told Fierce Biotech ahead of ESMO that today’s updated results “reaffirm zanidatamab’s potential as a foundational treatment for patients ...

Taking to the stage for the 2024 European Society for Medical Oncology (ESMO) Meeting in Barcelona, Spain, Exact Sciences said the study sought to simulate the screening population to predict the ...

This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.

Lantheus may have been hoping that “statistically significant” phase 3 data for its radioligand therapy would make a splash at ESMO, but not everyone is impressed. The biotech used the ...

Using a scoring system established a decade ago by the European Society of Medical Oncology (ESMO) to identify which approvals provide the highest clinical benefit, the researchers sorted the ...